Drug Utilization Review (DUR) Meeting Minutes

September 6, 2017

Members Present: Tanya Schmidt, Laura Schield, Jeffrey Hostetter, Michael Quast, Zach Marty, LeNeika Roehrich, Andrea Honeyman, Carlotta McCleary,

Members Absent: Michael Booth, Peter Woodrow, Gaylord Kavlie, Katie Kram, Wendy Brown,

Medicaid Pharmacy Department: Brendan Joyce, Alexi Murphy

Old Business

L. Roehrich served as Chair in the absence of W. Brown, and called the meeting to order at 1:00 p.m. Chair L. Roehrich asked for a motion to approve the minutes of the September meeting. L. Schield moved that the minutes be approved and Z. Marty seconded the motion. Chair L. Roehrich called for a voice vote to approve the minutes. The motion passed with no audible dissent.

Review Top 15 Therapeutic Categories/Top 25 Drugs

B. Joyce presented the quarterly review of the top 15 therapeutic classes by total cost of claims, top 25 drugs based on number of claims, and top 25 drugs based on claims cost for the 2nd quarter of 2017.

Sanford Update

Danny Weiss, representing Sanford Health Plan, spoke regarding ND Medicaid Expansion. In 2016, there were 19,506 average members per month with 102.2% of members utilizing benefits. The generic fill rate was 85.9%. The top 25 drugs represent 42.1% of total plan cost and 8 of the top 25 drugs are specialty drugs. The top 10 indications by cost represent 70.4% of total plan costs with the largest trend being in inflammatory conditions with a 71.5% increase from 2015.

Second Reviews

A motion and second was made at the June meeting to place Biltricide and Procysbi on prior authorization. The topics were brought up for a second review. There was no public comment. The motion to place Biltricide and Procysbi on prior authorization passed with no audible dissent.

PDL Update

A. Murphy shared with the Board all of the recommended PDL changes since the last 2017 version of the PDL was posted. Added to PA required were Kevzara to the Cytokine Modulators criteria, Morphabond ER to the Narcotics criteria, Ellzia Pak to the Kit criteria, Fabior to the Acne criteria, Brovana to the COPD criteria, Lialda and Apriso to the Inflammatory Bowel Agents criteria, Prednisolone sodium phosphate 10 mg/5 mL and 20 mg/5 mL to the Prednisolone Non-Solid Oral Dosage Forms criteria, Methyltest and methyltestosterone to the Oral Testosterone criteria, and Ilaris and Tymlos to the medications >$3,000 criteria. Xolair, Brineuria, and Ketamine were added to the Medical Billing Only list of medications, and Xifaxan 550 mg, Avonex, and Avonex pen will no longer require PA.

New Business

Juxtapid and Kynamro

B. Joyce presented updated criteria and a drug specific form for Juxtapid and Kynamro for the Board to review. There was no public comment. The motion to approve the updated criteria and form passed with no audible dissent.

Procysbi

B. Joyce presented updated criteria and a drug specific form for Procysbi for the Board to review. There was no public comment. The motion to approve the updated criteria and form passed with no audible dissent.

Tymlos and Miacalcin

B. Joyce presented updated criteria and a drug specific form for Tymlos and Miacalcin for the Board to review. There was no public comment. The motion to approve the updated criteria and form passed with no audible dissent.

Tardive Dyskinesia Agents

B. Joyce and A. Murphy presented updated criteria and a drug specific form for agents used to treat of tardive dyskinesia including Austedo, Ingrezza, and tetrabenazine. Maggie Murphy, representing Teva Pharmaceuticals, offered the opportunity to ask any questions regarding Austedo. Samantha Cicero, representing Neurocrine Biosciences, presented product information regarding Ingrezza. Z. Marty and L. Schield proposed amending the criteria for Ingrezza to require a trial of Austedo as opposed to a trial of tetrabenazine. The motion to approve the amended updated criteria and form passed with no audible dissent.

Jadenu

B. Joyce and A. Murphy presented updated criteria and a drug specific form for Jadenu for the Board to review. There was no public comment. The motion to approve the updated criteria and form passed with no audible dissent.

Review of Opioid Analgesic and Benzodiazepine Utilization

B. Joyce presented data showing current utilization of benzodiazepines, including use with and without opioid analgesics, rate of appropriate utilization for a diagnosis of anxiety, and utilization of multiple benzodiazepines. B. Joyce presented data showing utilization of opioid analgesics, including historic and current utilization of each individual agent by prescription count and average dose. The Board discussed potential provider education and drug edit opportunities.

Physician Prescribing Patterns for Select Therapeutic Categories

B. Joyce presented data showing the top prescriber utilization of select medications in therapeutic drug classes in order to evaluate utilization trends and potential outliers. Therapeutic classes evaluated included opioid analgesics, benzodiazepines, and gabapentin. Prescriber utilization was presented as number of prescriptions for, and patients currently on, selected medications, percent utilization of selected medications within their therapeutic class, and those with the highest number of patients on a high dose of select mediations.

Review of Stimulant Utilization Trends

B. Joyce presented stimulant utilization data trends over time, from 2001 to 2017. The data tracked the average daily dose per patient of each individual medication by age group. The data trends predominantly revealed increase in average daily dose overall with some exceptions in some age groups trending towards a dose decrease.

Criteria Recommendations

The recommended RDUR criteria enclosed in the packet were developed from product information provided by the manufacturers and are usually consistent with new indications, new drugs added, and new warnings. These proposed criteria will be added to the current set of criteria and will be used in future DUR cycles. J. Hostetter moved to approve the new criteria and Z. Marty seconded the motion. The motion passed with no audible dissent. The next DUR Board meeting will be held December 6, 2017 at the Capitol in the Brynhild Haugland room in Bismarck. L. Roehrich adjourned the meeting.